Inorganic Radiolabeled Nanomaterials in Cancer Therapy: A Review
Source abstract
Abstract
Cancer, one of the leading causes of death worldwide, remains a challenge to treat. Over the last decades, targeted therapies have emerged as a way to selectively target and treat the affected cells, leaving the healthy ones intact. Nanomaterials, with their high surface area, ease of functionalization, and interesting physicochemical properties, are seen as promising carriers for therapeutic radionuclides. Their optical, electronic, and magnetic properties can be supplemented by the emitted ionizing radiation to form theranostic (therapeutic and diagnostic) or combined therapeutic agents. This review describes how different relevant therapeutic radionuclides can be incorporated into inorganic nanoconstructs to be delivered to the cancer cells and their impact on tumors. Different types of nanomaterials as well as multiple ways of incorporating radionuclides and their impact on the stability and both in vitro and in vivo performances are discussed.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Radiopharmaceutical Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute for Nuclear Materials Science, Belgian Nuclear Research Center (SCK CEN), Mol 2400, Belgium
Department of Chemistry, KU Leuven, Leuven 3001, Belgium
Funding
SCK CEN Academy
References (100+)
Show source-provided references
1. 10.1016/j.ijrobp.2007.03.01410.1016/j.ijrobp.2007.03.014 ↗
2. 10.1016/j.clon.2014.09.00110.1016/j.clon.2014.09.001 ↗
3. 10.1080/17434440.2018.141905810.1080/17434440.2018.1419058 ↗
4. 10.3389/fonc.2019.0137810.3389/fonc.2019.01378 ↗
5. 10.1016/j.radonc.2004.01.00610.1016/j.radonc.2004.01.006 ↗
6. 10.1186/s40779-018-0167-410.1186/s40779-018-0167-4 ↗
7. 10.3389/fmolb.2014.0002410.3389/fmolb.2014.00024 ↗
8. 10.1016/j.addr.2015.12.00310.1016/j.addr.2015.12.003 ↗
9. 10.3413/Nukmed-0950-17-1210.3413/Nukmed-0950-17-12 ↗
10. 10.1053/j.semnuclmed.2008.05.00210.1053/j.semnuclmed.2008.05.002 ↗
11. 10.1021/acsnano.6b0604010.1021/acsnano.6b06040 ↗
12. 10.1021/ja057254a10.1021/ja057254a ↗
13. 10.1021/acsanm.8b0222910.1021/acsanm.8b02229 ↗
14. Kwatra D. · Translational Cancer Research · 2013 · 2 · 330
15. 10.1186/s11671-015-0864-910.1186/s11671-015-0864-9 ↗
16. 10.2967/jnumed.114.14601910.2967/jnumed.114.146019 ↗
17. 10.1021/nn405082y10.1021/nn405082y ↗
18. 10.1016/j.drudis.2006.07.00510.1016/j.drudis.2006.07.005 ↗
19. 10.1016/j.biomaterials.2019.11955310.1016/j.biomaterials.2019.119553 ↗
20. 10.7150/thno.734110.7150/thno.7341 ↗
21. 10.3390/jcm901008910.3390/jcm9010089 ↗
22. 10.1016/j.nucmedbio.2021.06.00110.1016/j.nucmedbio.2021.06.001 ↗
23. 10.3390/ma1401000410.3390/ma14010004 ↗
24. 10.1016/j.ccr.2021.21397410.1016/j.ccr.2021.213974 ↗
25. 10.1002/wnan.138610.1002/wnan.1386 ↗
26. 10.1038/318162a010.1038/318162a0 ↗
27. 10.1080/1536383080228164110.1080/15363830802281641 ↗
28. 10.1016/0010-2180(92)90010-M10.1016/0010-2180(92)90010-M ↗
29. 10.1039/C4OB01663G10.1039/C4OB01663G ↗
30. 10.1016/j.biomaterials.2008.05.00510.1016/j.biomaterials.2008.05.005 ↗
31. 10.1021/ja909361710.1021/ja9093617 ↗
32. 10.1148/radiol.1110256910.1148/radiol.11102569 ↗
33. 10.1021/bc300206q10.1021/bc300206q ↗
34. 10.1016/j.actbio.2017.08.01110.1016/j.actbio.2017.08.011 ↗
35. 10.1021/ja068639b10.1021/ja068639b ↗
36. 10.1088/0957-4484/20/38/38510210.1088/0957-4484/20/38/385102 ↗
37. 10.1038/354056a010.1038/354056a0 ↗
38. 10.1021/ar300004a10.1021/ar300004a ↗
39. 10.1039/C0NR00647E10.1039/C0NR00647E ↗
40. 10.7150/thno.1604710.7150/thno.16047 ↗
41. 10.1021/acsnano.9b0489810.1021/acsnano.9b04898 ↗
42. 10.1039/c3ra00154g10.1039/c3ra00154g ↗
43. 10.1016/j.carbon.2020.02.06010.1016/j.carbon.2020.02.060 ↗
44. 10.2147/ijn.s1330010.2147/ijn.s13300 ↗
45. 10.2967/jnumed.115.15831110.2967/jnumed.115.158311 ↗
46. Capello A. · Journal of Nuclear Medicine · 2003 · 44 · 98
47. 10.1016/j.nucmedbio.2008.04.00110.1016/j.nucmedbio.2008.04.001 ↗
48. 10.3389/fphar.2018.0133110.3389/fphar.2018.01331 ↗
49. 10.2967/jnumed.106.03913110.2967/jnumed.106.039131 ↗
50. 10.1038/nmat276610.1038/nmat2766 ↗
51. 10.1016/j.tibtech.2011.01.00810.1016/j.tibtech.2011.01.008 ↗
52. 10.1021/ja201017510.1021/ja2010175 ↗
53. 10.1021/cr300335p10.1021/cr300335p ↗
54. 10.1038/s41390-021-01681-610.1038/s41390-021-01681-6 ↗
55. 10.1021/acsanm.0c0252610.1021/acsanm.0c02526 ↗
56. 10.1016/j.biomaterials.2015.06.04310.1016/j.biomaterials.2015.06.043 ↗
57. 10.1039/C7NR08747K10.1039/C7NR08747K ↗
58. 10.1016/j.msec.2014.09.01910.1016/j.msec.2014.09.019 ↗
59. 10.1021/nn204625e10.1021/nn204625e ↗
60. 10.1021/acsanm.0c0307910.1021/acsanm.0c03079 ↗
61. 10.1021/acssuschemeng.7b0355710.1021/acssuschemeng.7b03557 ↗
62. 10.2147/IJN.S10302010.2147/IJN.S103020 ↗
63. 10.1021/mp500742y10.1021/mp500742y ↗
64. 10.1039/c0nr00735h10.1039/c0nr00735h ↗
65. 10.1021/acsami.5b1131810.1021/acsami.5b11318 ↗
66. 10.1021/jp905912n10.1021/jp905912n ↗
67. 10.1039/B812943F10.1039/B812943F ↗
68. 10.1039/C5RA25502C10.1039/C5RA25502C ↗
69. 10.1016/j.jpba.2018.01.05210.1016/j.jpba.2018.01.052 ↗
70. 10.1016/j.carbon.2017.02.08510.1016/j.carbon.2017.02.085 ↗
71. 10.1016/j.cossms.2016.06.00810.1016/j.cossms.2016.06.008 ↗
72. 10.1016/j.toxlet.2010.07.00110.1016/j.toxlet.2010.07.001 ↗
73. 10.1007/s10967-018-6330-210.1007/s10967-018-6330-2 ↗
74. 10.2147/IJN.S20354610.2147/IJN.S203546 ↗
75. 10.1166/jbn.2020.292810.1166/jbn.2020.2928 ↗
76. 10.1016/j.nantod.2018.12.00610.1016/j.nantod.2018.12.006 ↗
77. 10.3390/cancers1208202110.3390/cancers12082021 ↗
78. 10.3389/fchem.2019.0016710.3389/fchem.2019.00167 ↗
79. 10.1073/pnas.112117410910.1073/pnas.1121174109 ↗
80. 10.1039/C7DT00383H10.1039/C7DT00383H ↗
81. 10.1021/acs.iecr.8b0252610.1021/acs.iecr.8b02526 ↗
82. 10.1016/j.nucmedbio.2019.05.00510.1016/j.nucmedbio.2019.05.005 ↗
83. 10.1016/j.nano.2009.11.00110.1016/j.nano.2009.11.001 ↗
84. 10.1021/nn406258m10.1021/nn406258m ↗
85. 10.2967/jnmt.117.20636710.2967/jnmt.117.206367 ↗
86. 10.1002/slct.20180168510.1002/slct.201801685 ↗
87. 10.1039/C4TB01663G10.1039/C4TB01663G ↗
88. 10.1038/srep2061410.1038/srep20614 ↗
89. 10.1002/adhm.20160112010.1002/adhm.201601120 ↗
90. 10.1002/adhm.20200200910.1002/adhm.202002009 ↗
91. 10.1002/jlcr.291010.1002/jlcr.2910 ↗
92. 10.1166/jbn.2014.172110.1166/jbn.2014.1721 ↗
93. 10.1021/acs.molpharmaceut.5b0042510.1021/acs.molpharmaceut.5b00425 ↗
94. 10.2967/jnumed.115.16890610.2967/jnumed.115.168906 ↗
95. 10.3390/ijms2302061710.3390/ijms23020617 ↗
96. 10.1016/j.nantod.2021.10114410.1016/j.nantod.2021.101144 ↗
97. 10.1016/j.apradiso.2017.10.03010.1016/j.apradiso.2017.10.030 ↗
98. 10.1039/C7RA06376H10.1039/C7RA06376H ↗
99. 10.3390/nano904063210.3390/nano9040632 ↗
100. 10.3390/pharmaceutics1202018810.3390/pharmaceutics12020188 ↗